Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer

Acta Biomaterialia(2021)10.1016/j.actbio.2021.05.018Source: DataRank Database

Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer is a research paper published in Acta Biomaterialia (2021). On theSindex it has a DataRank of 0. It has been cited 51 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access51 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 4.17)OA: greenTopics (37)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Danlei Yu,Shi‐Yong Sun ORCID,Feng Li ORCID,Chen Wu ORCID

Live enrichment

PubMed:34048974 OpenAlex:https://openalex.org/W3165692960

National Cancer Institute

Grant: P50 CA217691

National Cancer Institute

Grant: R01 CA223220

National Cancer Institute

Grant: R01 CA245386

National Cancer Institute

Grant: UG1 CA233259

FWCI

4.17

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8273131

publisherhttps://api.elsevier.com/content/article/PII:S1742706121003287?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1742706121003287?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.actbio.2021.05.018

Fields of Study

Lung Cancer Treatments and MutationsCancer therapeutics and mechanismsLung Cancer Research Studies

MeSH Terms

AcrylamidesAniline CompoundsBenzimidazolesCarcinoma, Non-Small-Cell LungHumansIndolesLung NeoplasmsMutationPyrimidinesDrug Resistance, NeoplasmProtein Kinase InhibitorsNanoparticlesTumor MicroenvironmentErbB Receptors

Keywords

OsimertinibSelumetinibCancer researchT790Mnon-small cell lung cancer (NSCLC)PEG ratioMedicineMAPK/ERK pathwayLung cancerKinaseCancerChemistryEpidermal growth factor receptorGefitinibErlotinibOncologyA549 cellMEK inhibitorInternal medicineBiochemistry

Sustainable Development Goals

SDG 0: Good health and well-being